Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Apriso in Ulcerative Colitis Remission
NCT00326209Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Dec 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Salcrozine in ulcerative colitis (UC), sponsored by Valeant Pharmaceuticals. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at 24.5 months, Number of Participants Who Prematurely Discontinued Treatment at 24 months and 2 more. Started Dec 2005; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00326209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326209.